Macrophage inflammation resolution requires CPEB4-directed offsetting of mRNA degradation

Abstract

Chronic inflammation is a major cause of disease. Inflammation resolution is in part directed by the differential stability of mRNAs encoding pro-inflammatory and anti-inflammatory factors. In particular, tristetraprolin (TTP)-directed mRNA deadenylation destabilizes AU-rich element (ARE)-containing mRNAs. However, this mechanism alone cannot explain the variety of mRNA expression kinetics that are required to uncouple degradation of pro-inflammatory mRNAs from the sustained expression of anti-inflammatory mRNAs. Here we show that the RNA-binding protein CPEB4 acts in an opposing manner to TTP in macrophages: it helps to stabilize anti-inflammatory transcripts harboring cytoplasmic polyadenylation elements (CPEs) and AREs in their 3′-UTRs, and it is required for the resolution of the LPS-triggered inflammatory response. Coordination of CPEB4 and TTP activities is sequentially regulated through MAPK signaling. Accordingly, CPEB4 depletion in macrophages impairs inflammation resolution in an LPS-induced sepsis model. We propose that the counterbalancing actions of CPEB4 and TTP, as well as the distribution of CPEs and AREs in their target mRNAs, define transcript-specific decay patterns required for inflammation resolution. Thus, these two opposing mechanisms provide a fine-tuning control of inflammatory transcript destabilization while maintaining the expression of the negative feedback loops required for efficient inflammation resolution; disruption of this balance can lead to disease.

Data availability

Raw data for RIP-seq and RNA-seq datasets are available in GEO (accession number GSE160191 and GSE160346, respectively). Numerical data from genome-wide experiments and motif analysis are available in supplementary tables 1-6. All blots shown and used for quantifications have been provided as source data.Scripts are available as Supplementary files 9.

The following data sets were generated

Article and author information

Author details

  1. Clara Suñer

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  2. Annarita Sibilio

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  3. Judit Martín

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  4. Chiara Lara Castellazzi

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  5. Oscar Reina

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  6. Ivan Dotu

    Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  7. Adrià Caballé

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  8. Elisa Rivas

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  9. Vittorio Calderone

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  10. Juana Díez

    Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  11. Angel R Nebreda

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    For correspondence
    angel.nebreda@irbbarcelona.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7631-4060
  12. Raúl Méndez

    Institute for Research in Biomedicine (IRB), Barcelona, Spain
    For correspondence
    raul.mendez@irbbarcelona.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1952-6905

Funding

Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (BFU2017-83561-P)

  • Raúl Méndez

BBVA Foundation

  • Raúl Méndez

la Caixa" Foundation "

  • Raúl Méndez

Fundación Científica Asociación Española Contra el Cáncer

  • Raúl Méndez

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations of the Euopean Directive 2010/63/EU on the protection of animals used for scientific purposes. All experimental protocols were approved by the Animal Ethics Committee at the Parc Cientific de Barcelona.

Copyright

© 2022, Suñer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,405
    views
  • 308
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Clara Suñer
  2. Annarita Sibilio
  3. Judit Martín
  4. Chiara Lara Castellazzi
  5. Oscar Reina
  6. Ivan Dotu
  7. Adrià Caballé
  8. Elisa Rivas
  9. Vittorio Calderone
  10. Juana Díez
  11. Angel R Nebreda
  12. Raúl Méndez
(2022)
Macrophage inflammation resolution requires CPEB4-directed offsetting of mRNA degradation
eLife 11:e75873.
https://doi.org/10.7554/eLife.75873

Share this article

https://doi.org/10.7554/eLife.75873

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.

    1. Cell Biology
    2. Genetics and Genomics
    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.